Intellectual Property India Publishes Patent Application for 'Proteins Binding Nkg2d, Cd16, And Ceacam5' Filed by Merck Sharp & Dohme Llc; and Dragonfly Therapeutics, Inc.

MUMBAI, India, March 7 -- Intellectual Property India has published a patent application (202517014387 A) filed by Merck Sharp & Dohme Llc; and Dragonfly Therapeutics, Inc., Rahway, U.S.A., on Feb. 19, for 'proteins binding nkg2d, cd16, and ceacam5.'

Inventor(s) include Beebe, Amy M.; Fayadat-Dilman, Laurence; Jaun, Veronica M.; Chang, Gregory P.; Chattopadhyay, Souvik; Cheung, Ann F.; Grinberg, Asya; Hein, Pyae P.; and Wagtmann, Nicolai.

The application for the patent was published on March 7, under issue no. 10/2025.

According to the abstract released by the Intellectual Property India: "Multi-specific binding proteins that bind NKG2D, CD16, and CEACAM5 are described, as well as pharmaceutical compositions and therapeutic methods usefu...